Printer Friendly

QUADRA LOGIC BEGINS BOSTON CLINICAL TRIAL OF NEW DRUG AS A POTENTIAL TREATMENT FOR PSORIASIS

 VANCOUVER, British Columbia, Jan. 7 /PRNewswire/ -- Quadra Logic Technologies Inc. (NASDAQ-NMS: QLTIF; Toronto, Vancouver: QLT) (QLT) announced today that it has begun a clinical trial of its proprietary light-activated drug, Benzoporphyrin derivative (also known as BPD), as a potential treatment for psoriasis.
 The Phase I/II clinical trial -- which began this week at the Massachusetts General Hospital in Boston -- is being conducted under the direction of Drs. Rox Anderson and Luciann Hruza from the Wellman Laboratories of Photomedicine and the division of Dermatology of the Harvard Medical School. The Boston study is the first clinical trial of BPD as a potential treatment for a disease condition other than cancer.
 "Preliminary research suggests that BPD may be effective in treating a variety of diseases that are characterized by rapidly dividing cells which are fed by an abnormal blood supply, such as cancer, psoriasis, and the reclosing of arteries following balloon angioplasty," says Dr. Julia Levy, senior vice president of Discovery at QLT.
 "Based on our research experience with cancer, we believe there is a common thread in the way that BPD accumulates in diseased tissue."
 Psoriasis is skin growth gone awry and may affect between 1 percent and 3 percent of the North American population. In severe cases, unsightly and debilitating lesions containing white blood cells develop. Normally skin cells mature and shed in 28 to 30 days, making way for new cells. With psoriasis, new skin cells develop seven times faster than normal. They pile up forming raised, scaly plaques. Blood supply to the afflicted area is sharply increased, and an unusually high number of white blood cells migrate to the outer layers of the skin. The scalp, elbows, trunk and lower parts of the body are the commonly affected areas.
 During the Boston trial, patients suffering from psoriasis will be injected intravenously with BPD and exposed to light from a medical laser. The patients in this trial are being treated as outpatients and leave the hospital after a short observation period.
 Levy says molecules of the drug attach themselves -- not unlike hitchhikers -- to the lipoprotein components of blood.
 "Abnormal tissues, such as cancer or psoriasis lesions, and the blood vessels feeding them, contain higher than average concentrations of receptors for lipoproteins, thereby acting as a highly effective delivery system that carries the drug to targeted tissues. When switched on' by light, the drug produces a toxic form of oxygen that will destroy or alter the disease-causing cells while having minimal effect on surrounding healthy tissue."
 The process of treating disease conditions with light-activated drugs is known as Photodynamic Therapy. Quadra Logic is the world leader in this field.
 BPD is Quadra Logic's second-generation photosensitive drug. First identified by researchers at Quadra Logic and the University of British Columbia, BPD is one of only a few drugs to be discovered and developed by a Canadian company.
 American Cyanamid Co. is QLT's co-development, marketing and distribution partner for cancer and dermatology applications of Photodynamic Therapy.
 Quadra Logic is a pharmaceutical corporation engaged in the research, development and commercialization of photosensitive drugs for the treatment and prevention of disease.
 -0- 1/7/93
 /CONTACT: David J. Main, manager-Investor Relations of Quadra Logic Technologies, 604-872-7881, or 800-663-5486/
 (QLTIF QLT.)


CO: Quadra Logic Technologies Inc. ST: British Columbia IN: MTC SU:

JB -- LA010 -- 2542 01/07/93 09:47 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1993
Words:556
Previous Article:THRIFTY TEL INC. ACQUIRES SOUTHERN CALIFORNIA LONG DISTANCE TELEPHONE SERVICE COMPANY
Next Article:PLAZA HOME MORTGAGE POSTS RECORD DECEMBER LOAN ORIGINATIONS
Topics:


Related Articles
AGOURON PHARMACEUTICALS CLEARED TO COMMENCE CLINICAL TESTING OF PSORIASIS DRUG
AGOURON PHARMACEUTICALS BEGINS CLINICAL TESTING OF PSORIASIS DRUG
QUADRA LOGIC BEGINS SKIN CANCER TRIALS OF NEW DRUG IN CANADA
QUADRA LOGIC TECHNOLOGIES INC. ANNOUNCES RESULTS OF TESTS
QLT RECEIVES FIRST EUROPEAN APPROVAL FOR PHOTOFRIN(R); HOLLAND APPROVAL EXPANDS USE TO LUNG AND ESOPHAGEAL CANCERS
QUADRA LOGIC RECEIVES JAPANESE APPROVAL FOR PHOTOFRIN(R)
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF PHOTOFRIN(R)
THE IMMUNE RESPONSE CORPORATION BEGINS PSORIASIS PHASE II CLINICAL TRIAL
MedImmune and BioTransplant Announce Plans to Test New Drug for Psoriasis

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters